Garbiñe Ezcurra Díaz

Garbiñe Ezcurra Díaz

Auto-generated profile, based on publicly available information

Garbiñe Ezcurra Díaz

Hospital de la Santa Creu i Sant Pau

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Neurology
Verified
Journal Article
Closed access
MGMarina Guasch-Jiménez
Marina Guasch-Jiménez
GDGarbiñe Ezcurra Díaz
Garbiñe Ezcurra Díaz
ÁLÁlvaro Lambea-Gil
Álvaro Lambea-Gil
ARAnna Ramos-Pachón
Anna Ramos-Pachón
AMAlejandro Martinez-Domeño
Alejandro Martinez-Domeño
A(as the Catalan Stroke Code and Reperfusion Consortium (CICAT)
as the Catalan Stroke Code and Reperfusion Consortium (CICAT)
In patients with acute ischemic stroke (AIS), the impact of hemorrhagic transformation (HT) after endovascular treatment (EVT) on poorer stroke outcome is well established when associated with clinical deterioration. However, the influence of asymptomatic HT remains unclear. We aimed to examine the impact of asymptomatic HT after EVT on functional outcome and mortality. Drawing on Catalan (Spain) population-based prospective stroke registry data, we included patients from 10 comprehensive stroke centers with anterior circulation AIS (2017-2023) who underwent EVT, excluding patients without data on the presence of HT or functional outcome at 3 months of follow-up. HT was categorized as parenchymal hemorrhage (PH), hemorrhagic infarct (HI) types 1 and 2, and remote PH (rPH). Asymptomatic HT was defined as any HT not causing death or the NIH Stroke Scale (NIHSS) score to increase by ≥ 4 points. Functional outcome was centrally assessed using the modified Rankin Scale (mRS). The primary end point was a shift in the 3-month mRS score. After excluding symptomatic intracerebral hemorrhage (sICH), multivariable ordinal regression analyses (adjusted by age, mRS, baseline NIHSS score, baseline Alberta Stroke Program Early CT Score, and modified Thrombolysis In Cerebral Infarction score ≥2b) were performed to test for asymptomatic HT association with the primary end point. We included 3,067 patients (72.0 ± 13.6 years, 50.7% women), 179 (5.8%) with sICH and 612 (20.0%) with asymptomatic HT. HT category frequencies were 8.9% HI1, 7.2% HI2, 4.4% PH1, 3.8% PH2, and 1.5% rPH. The percentage of asymptomatic patients showed a hierarchical distribution, ranging from 93.4% in HI1 to 25.0% in PH2. In the multivariable analysis, asymptomatic HT was associated with poorer outcomes (common odds ratio [cOR] 2.24, 95% CI 1.89-2.66) and higher mortality (adjusted odds ratio 1.50, 95% CI 1.17-1.91). In the sensitivity analyses, the association with functional outcome remained significant for each HT category, with asymptomatic PH2 showing the highest odds of poorer outcomes (cOR 3.15, 95% CI 1.46-6.83). In patients with AIS undergoing EVT, asymptomatic HT was associated with poorer functional outcomes and higher mortality, suggesting that any HT, regardless of its clinical impact or radiologic category, should be considered as an additional EVT safety measure.

1 June 2024 in European Stroke Journal
Verified
Journal Article
Closed access
ABAlejandro Bustamante
Alejandro Bustamante
MBMarta Balboa
Marta Balboa
GEGarbiñe Ezcurra
Garbiñe Ezcurra
ASAdrián Sánchez-Fortún Sánchez
Adrián Sánchez-Fortún Sánchez
JRJudith Ruiz
Judith Ruiz
SRSusana Ruiz-Bilbao
Susana Ruiz-Bilbao
Introduction: Reperfusion therapies represent promising treatments for patients with Central Retinal Artery Occlusion (CRAO), but access is limited due to low incidence and lack of protocols. We aimed to describe the benefit of implementing a Retinal Stroke-Code protocol regarding access to reperfusion, visual acuity and aetiological assessment. Patients and methods: Prospective cohort study performed at a Comprehensive Stroke Centre. Criteria for activation were sudden monocular, painless vision loss within 6 h from onset. Eligible patients received IAT when immediately available and IVT otherwise. All patients were followed by ophthalmologists to assess best-corrected visual acuity (BCVA) and visual complications, and by neurologists for aetiological workup. Visual amelioration was defined as improvement of at least one Early Treatment Diabetic Retinopathy Study (ETDRS) letter from baseline to 1 week. Results: Of 49 patients with CRAO, 15 (30.6%) received reperfusion therapies (12 IVT, 3 IAT). Presentation beyond 6 h was the main contraindication. Patients receiving reperfusion therapies had better rates of visual improvement (33.3% vs 5.9%, p = 0.022). There were no complications related to reperfusion therapies. Rates of neovascular glaucoma were non-significantly lower in patients receiving reperfusion therapies (13.3% vs 20.6%, p = 0.701). Similar rates of atherosclerotic, cardioembolic and undetermined aetiologies were observed, leading to 10 new diagnosed atrial fibrillation and five carotid revascularizations. Conclusion: A comprehensive acute management of CRAO is feasible despite low incidence. In our study, reperfusion therapies were safe and associated with higher rates of visual recovery. A similar etiological workup than ischemic stroke led to of high proportion of underlying aetiologies.

23 July 2024 in Neurology
Verified
Journal Article
Closed access
JMJoan Marti-Fabregas
Joan Marti-Fabregas
ARAnna Ramos-Pachón
Anna Ramos-Pachón
LPLuis Prats-Sanchez
Luis Prats-Sanchez
ANAna Núñez-Guillén
Ana Núñez-Guillén
BRBlanca Lara Rodríguez
Blanca Lara Rodríguez
FHFor Hic-Cat
For Hic-Cat
Whether the outcome of patients with spontaneous intracerebral hemorrhage (ICH) differs depending on the type of hospital where they are admitted is uncertain. The objective of this study was to determine influence of hospital type at admission (telestroke center [TSC], primary stroke center [PSC], or comprehensive stroke center [CSC]) on outcome for patients with ICH. We hypothesized that outcomes may be better for patients admitted to a CSC. This is a multicenter prospective observational and population-based study of a cohort of consecutively recruited patients with ICH (March 2020-March 2022). We included all patients with spontaneous ICH in Catalonia (Spain) who had a pre-ICH modified Rankin scale (mRS) score of 0-3 and who were admitted to the hospital within 24 hours of onset. We compared patients admitted to a TSC/PSC (n = 641) or a CSC (n = 1,320) and also analyzed the subgroup of patients transferred (n = 331) or not transferred (n = 310) from a TSC/PSC to a CSC. The main outcome was the 3-month mRS score obtained by blinded investigators. Outcomes were compared using adjusted ordinal logistic regression to estimate the common odds ratio (OR) and 95% CI for a shift in mRS scores. A propensity score matching (PSM) analysis was performed for the subgroup of transferred patients. Relevant data were obtained from 1961 of a total of 2,230 patients, with the mean (SD) age of 70 (14.1) years, and 713 (38%) patients were women. After adjusting for confounders (age, NIH Stroke Scale score, intraventricular hemorrhage, hematoma volume, and pre-ICH mRS score), type of hospital of initial admission (CSC vs TSC/PSC) was not associated with outcome (adjusted common OR 1.13, 95% CI 0.93-1.38). A PSM analysis indicated that transfer to a CSC was not associated with more favorable outcomes (OR 0.77, 95% CI 0.55-1.10; p = 0.16). In this population-based study, we found that, after adjusting for confounders, hospital types were not associated with functional outcomes. In addition, for patients who were transferred from a TSC/PSC to a CSC, PSM indicated that outcomes were similar to nontransferred patients. Our findings suggest that patient characteristics are more important than hospital characteristics in determining outcome after ICH. ClinicalTrials.gov Identifier: NCT03956485.

9 April 2024 in Neurology
Verified
Journal Article
Closed access
LPLuis Prats-Sanchez
Luis Prats-Sanchez
PCPol Camps-Renom
Pol Camps-Renom
PNPhilip S. Nash
Philip S. Nash
DWDuncan Wilson
Duncan Wilson
GAGareth Ambler
Gareth Ambler
F(for the Microbleeds International Collaborative Network (MICON)
for the Microbleeds International Collaborative Network (MICON)
The association between statin use and the risk of intracranial hemorrhage (ICrH) following ischemic stroke (IS) or transient ischemic attack (TIA) in patients with cerebral microbleeds (CMBs) remains uncertain. This study investigated the risk of recurrent IS and ICrH in patients receiving statins based on the presence of CMBs. We conducted a pooled analysis of individual patient data from the Microbleeds International Collaborative Network, comprising 32 hospital-based prospective studies fulfilling the following criteria: adult patients with IS or TIA, availability of appropriate baseline MRI for CMB quantification and distribution, registration of statin use after the index stroke, and collection of stroke event data during a follow-up period of ≥3 months. The primary endpoint was the occurrence of recurrent symptomatic stroke (IS or ICrH), while secondary endpoints included IS alone or ICrH alone. We calculated incidence rates and performed Cox regression analyses adjusting for age, sex, hypertension, atrial fibrillation, previous stroke, and use of antiplatelet or anticoagulant drugs to explore the association between statin use and stroke events during follow-up in patients with CMBs. In total, 16,373 patients were included (mean age 70.5 ± 12.8 years; 42.5% female). Among them, 10,812 received statins at discharge, and 4,668 had 1 or more CMBs. The median follow-up duration was 1.34 years (interquartile range: 0.32-2.44). In patients with CMBs, statin users were compared with nonusers. Compared with nonusers, statin therapy was associated with a reduced risk of any stroke (incidence rate [IR] 53 vs 79 per 1,000 patient-years, adjusted hazard ratio [aHR] 0.68 [95% CI 0.56-0.84]), a reduced risk of IS (IR 39 vs 65 per 1,000 patient-years, aHR 0.65 [95% CI 0.51-0.82]), and no association with the risk of ICrH (IR 11 vs 16 per 1,000 patient-years, aHR 0.73 [95% CI 0.46-1.15]). The results in aHR remained consistent when considering anatomical distribution and high burden (≥5) of CMBs. These observational data suggest that secondary stroke prevention with statins in patients with IS or TIA and CMBs is associated with a lower risk of any stroke or IS without an increased risk of ICrH. This study provides Class III evidence that for patients with IS or TIA and CMBs, statins lower the risk of any stroke or IS without increasing the risk of ICrH.

1 September 2025 in European Stroke Journal
Verified
Journal Article
Closed access
RCRoger Collet-Vidiella
Roger Collet-Vidiella
PCPol Camps-Renom
Pol Camps-Renom
ANAna Núñez-Guillén
Ana Núñez-Guillén
HQHelena Quesada
Helena Quesada
FRFederica Rizzo
Federica Rizzo
JMJoan Marti-Fabregas
Joan Marti-Fabregas
Introduction: The efficacy of intracranial rescue stenting (RS) following failed mechanical thrombectomy (MT) in large-vessel occlusion (LVO) stroke remains uncertain. We aimed to evaluate clinical outcomes of RS in patients with anterior circulation LVO stroke following unsuccessful MT. Patients and methods: We conducted a retrospective analysis using the Stroke Code Registry of Catalonia (January 2016–March 2022), a prospective, population-based registry including patients treated at 10 comprehensive stroke centers. We compared outcomes between patients who received RS and those who did not after failed MT. The primary outcome was the shift in 90-day functional status, assessed by the modified Rankin Scale (mRS), adjusted for confounders using inverse probability of treatment weighting (IPTW). Secondary outcomes included good (mRS ⩽ 2 or 3 if baseline mRS was 3) and excellent (mRS ⩽ 1) outcomes, ischemic recurrences, hemorrhagic transformation, and 90-day mortality. Results: Of 601 patients, 69 underwent RS. RS did not significantly impact the 90-day mRS shift (adjusted common odds ratio [acOR] 1.06, [95% CI 0.85–1.32]; p = 0.613). However, RS was associated with higher rates of good (18.8% vs 11.7%; aOR 1.41, [95% CI 1.00–1.99]; p = 0.048) and excellent outcomes (17.4% vs 5.7%; aOR 2.90, [95% CI 1.89–4.43]; p < 0.001). Symptomatic intracranial hemorrhage (9.4% vs 7.4%; p = 0.507) and 90-day mortality (30.4% vs 39.8%; p = 0.135) were similar between groups. Stroke recurrence (4.2% vs 1.7%; p = 0.247) showed no significant difference at 33-month follow-up. Discussion and conclusion: RS may increase the likelihood of good and excellent outcomes in anterior LVO stroke after failed MT, without increasing long-term risks. Further randomized trials are warranted for comprehensive validation.

21 July 2025 in European Journal of Neurology
Verified
Journal Article
Open access
MLMiquel Lledós
Miquel Lledós
LPLuís Prats‐Sánchez
Luís Prats‐Sánchez
EMElena Muiño
Elena Muiño
NCNatalia Cullell
Natalia Cullell
LLLaia Llucià‐Carol
Laia Llucià‐Carol
IFIsrael Fernandez
Israel Fernandez
Background: Functional recovery from ischemic stroke (IS), the main cause of adult disability worldwide, is influenced by many factors, and a portion of interindividual variability remains unexplained.Methods: Observational study in a tertiary stroke centre of patients with IS analyzed using shotgun metagenomic sequencing (January 2020–March 2022). Functional outcomes were assessed according to modified Rankin Scale (mRS) scores 3‐months post‐IS, considering 0–2 favorable and 3–6 unfavorable. The causal relationship between several bacteria and post‐IS outcomes was explored via two‐sample Mendelian randomization (MR) analyses using Genome‐Wide Association Analysis (GWAS) summary statistics.Results: Comparing 128 patients with favorable and unfavorable post‐IS functional outcomes, β‐diversity analysis showed a separation in microbial structure, and α‐diversity measures revealed greater bacterial richness in the favorable outcomes group. Taxonomic profiling of the samples showed that a greater abundance of pathogenic bacteria (e.g., Pseudomonas, Finegoldia, Porphyromonas) was associated with an unfavorable outcome. Functional profiling of the samples revealed differences in the ethylbenzene degradation pathway and in 16S rRNA (uracil1498‐N3)‐methyltransferase. MR confirmed increased pyruvate levels to be causally associated with post‐IS favorable outcomes (β = −0.50, 95% CI: −0.91, −0.10).Conclusions: Our study points to gut microbiota differences in patients with unfavorable versus favorable 3‐month post‐IS outcomes. Patients with unfavorable outcomes presented gut microbiota dysbiosis and alterations in multiple metabolic pathways.Trial Registration: This study was registered on 3 October 2021 with https://clinicaltrials.gov. Access number: NCT04795687